Allergen immunotherapy and asthma: Pediatric Allergy and Immunology

M.A. Tosca, R. Olcese, A. Licari, G. Ciprandi

Research output: Contribution to journalArticlepeer-review

Abstract

Allergen immunotherapy (AIT) represents at present the unique disease-modifying treatment strategy for IgE-mediated allergic diseases. AIT can induce clinical improvement of allergic asthma, including reduced symptoms, medication use, and improvement of quality of life, with a long-lasting effect after cessation of treatment. Notably, the current asthma guidelines are now recommending sublingual immunotherapy as an add-on therapy for asthma in adults and adolescents with house dust mite allergy. Clinical indications of AIT, with particular reference to pediatric asthma, mechanisms of clinical and immunological tolerance to allergens, and the potential biomarkers predicting clinical response are discussed. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Original languageEnglish
Pages (from-to)46-48
Number of pages3
JournalPediatr. Allergy Immunol.
Volume31
Issue numberS24
DOIs
Publication statusPublished - 2020

Keywords

  • allergen immunotherapy
  • allergic asthma
  • subcutaneous immunotherapy
  • sublingual immunotherapy
  • Article
  • asthma
  • desensitization
  • house dust allergy
  • human
  • immunological tolerance
  • priority journal
  • quality of life
  • adolescent
  • adult
  • allergic rhinitis
  • child
  • immunology
  • procedures
  • subcutaneous drug administration
  • sublingual drug administration
  • treatment outcome
  • pharmacological biomarker
  • Administration, Sublingual
  • Adolescent
  • Adult
  • Asthma
  • Biomarkers, Pharmacological
  • Child
  • Desensitization, Immunologic
  • Humans
  • Immune Tolerance
  • Injections, Subcutaneous
  • Rhinitis, Allergic
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Allergen immunotherapy and asthma: Pediatric Allergy and Immunology'. Together they form a unique fingerprint.

Cite this